Every 8-K that Innoviva, Inc. (INVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INVA filings page.
Innoviva, Inc. reported second quarter 2026 results featuring higher revenue but a net loss driven by investment fair value movements. Total revenue for the quarter ended June 30, 2026 was $119.6 million, with royalty revenue, net of capitalized fee amortization, of $56.3 million, net product sales of $51.8 million, and license and other revenue of $11.5 million. Income from operations was $50.9 million, but large negative changes in the fair values of equity method investments of $(131.8) million and equity and long-term investments of $(29.2) million led to a net loss of $(83.4) million, compared with net income of $63.7 million a year earlier.
For the first six months of 2026, total revenue was $217.6 million and net income was $103.2 million, indicating strong year-to-date profitability despite the second-quarter loss. Cash and cash equivalents were $570.4 million as of June 30, 2026, supported by $87.3 million of net cash provided by operating activities in the first half. The Innoviva Specialty Therapeutics platform generated U.S. net product sales of $36.6 million in the quarter, representing 26% year-over-year growth, and management stated it remains on track to achieve at least $150 million in IST U.S. net product sales in 2026. The company also highlighted a commercialization and licensing agreement with Dr. Reddy’s Laboratories for XACDURO in emerging markets and the launch of Nortiva Bio, a wholly owned strategic healthcare asset focused on extended-release oral drug delivery.
Innoviva, Inc. reported board changes and new director compensation. On May 12, 2026, directors Derek Small and Mark DiPaolo resigned to focus on Syndeio BioSciences, where Innoviva has made a series of investments, and the resignations were not due to any disagreement with the company.
On May 18, 2026, the board elected veteran investment executive Josephine Linden as a director, with the expectation she will serve on the Audit Committee. The board determined she qualifies as an independent director under SEC and Nasdaq rules, and disclosed no related-party transactions exceeding $120,000.
Under Innoviva’s non-employee director compensation program, Linden will receive RSU awards valued at $125,000 and $206,250, plus options to purchase 9,166 shares. These equity awards vest over one to two years, with accelerated vesting upon death, disability, or a change in control of the company.
Innoviva, Inc. reported a profitable first quarter of 2026, with total revenue of $97,994 thousand and net income of $186,595 thousand. Diluted earnings per share were $2.22, compared with a diluted net loss per share of $0.74 a year earlier.
Royalty revenue, net, was $55,167 thousand, while net product sales rose to $41,371 thousand. Management highlighted Innoviva Specialty Therapeutics, noting IST net product sales growth of 37% year over year, including 29% growth in U.S. sales.
Results were boosted by changes in fair values of equity method investments of $157,650 thousand and equity and long-term investments of $33,575 thousand. Cash and cash equivalents increased to $603,085 thousand as of March 31, 2026, supported by positive operating and investing cash flows.
Innoviva, Inc. reported results from its Annual Meeting of Stockholders held on May 4, 2026. Stockholders elected five directors for one-year terms ending at the 2027 annual meeting, including Chief Executive Officer Pavel Raifeld, with each nominee receiving a strong majority of votes cast.
Stockholders approved, on a non-binding advisory basis, Innoviva’s executive compensation and ratified the Audit Committee’s selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved Innoviva’s 2026 Equity Incentive Plan, supporting the company’s ongoing compensation and governance framework.
Innoviva reported strong growth for 2025, with total revenue rising to $411.3M from $358.7M and net income jumping to $271.2M from $23.4M. Fourth quarter 2025 revenue was $114.6M and net income was $164.2M.
The core royalties portfolio generated $250.3M of 2025 revenue, while Innoviva Specialty Therapeutics delivered U.S. net product sales of $119.2M, up 47% year over year. Cash and cash equivalents increased to $550.9M, supported by $196.9M in operating cash flow. The company highlighted U.S. FDA approval of NUZOLVENCE, the mid‑2025 U.S. launch of ZEVTERA, and initiated a $125M share repurchase program, while indicating an expectation of at least $150M in IST U.S. net product sales in 2026.
Innoviva, Inc. (INVA) furnished an 8-K announcing its quarterly results press release. On November 5, 2025, the company provided a press release covering results for the quarter ended September 30, 2025, attached as Exhibit 99.1. The disclosure under Item 2.02 is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless specifically stated.